Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14600317 | 0.89 | ALDH1A1 (0.45) | ALDH1A1L3MBTL1KDM4EGAAMAPT | |
| SCHEMBL12243881 | 0.80 | MEN1 (0.49) | ALDH1A1L3MBTL1KDM4EGAAMAPT | |
| SCHEMBL9319296 | 0.79 | MAPT (0.54) | ALDH1A1L3MBTL1KDM4EGAAMAPT | |
| SCHEMBL10483978 | 0.79 | GAA (0.47) | ALDH1A1L3MBTL1KDM4EGAAMAPT | |
| SCHEMBL5040770 | 0.79 | SLC6A2 (0.47) | ALDH1A1L3MBTL1KDM4EGAAMAPT | |
| SCHEMBL13699060 | 0.79 | CPB2 (0.46) | ALDH1A1L3MBTL1KDM4EMAPTLMNA | |
| SCHEMBL594105 | 0.78 | RAB9A (0.51) | ALDH1A1L3MBTL1KDM4EGAAMAPT | |
| SCHEMBL26082876 | 0.78 | ALDH1A1 (0.40) | ALDH1A1L3MBTL1KDM4EGAAMAPT | |
| SCHEMBL8245704 | 0.77 | ALDH1A1 (0.47) | ALDH1A1L3MBTL1KDM4EGAAMAPT | |
| SCHEMBL21469023 | 0.76 | MAPT (0.54) | ALDH1A1L3MBTL1KDM4EGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7589067-B2 | 6, 11-bridged tricyclic macrolides | ENANTA PHARMACEUTICALS, INC. (US) | 2009-09-15 | — | — | US | disclosed |
| US-20080039406-A1 | 3,6-BRIDGED TYLOSIN DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2008-02-14 | — | — | US | disclosed |
| US-20080039406-A1 | 3,6-BRIDGED TYLOSIN DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2008-02-14 | — | — | US | disclosed |
| US-20070082853-A1 | 6, 11-bridged tricyclic macrolides | ENANTA PHARMACEUTICAL, INC. | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082853-A1 | 6, 11-bridged tricyclic macrolides | CYP2B6, CYP2D6, ABCB11 | ALDH1A1 1193/4885L3MBTL1 2779/4885KDM4E 1806/4885 |
| US-20080039406-A1 | 3,6-BRIDGED TYLOSIN DERIVATIVES | ABCB11, ABCB1, CYP2B6 | ALDH1A1 1995/4885L3MBTL1 2288/4885KDM4E 1869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.